克里斯托弗·博恩尔
Christopher Boerner
领导U.S.大型Pharmaceuticals企业运营
专业领域
Healthcare management, life sciences
核心贡献
领导U.S.大型Pharmaceuticals企业运营
Leading large-scale Pharmaceuticals operations in U.S.
最新观点
-
百时美施贵宝董事会主席兼CEO博尔纳在2026年Q3业绩中表示,增长组合再次实现两位数增长(同比增12%),体现多元组合的持续动能;首个同类CELMoD药物Zenbexus获批为多发性骨髓瘤患者带来全新治疗类别,是近期多项管线里程碑之一。展望近期更多后期数据,公司将继续有纪律地执行、把钱投向机会最大的领域,夯实可持续增长的基础。Q3营收130.69亿美元、同比增长7%,全年营收指引上调至497.5亿~502.5亿美元。
We delivered another quarter of double-digit growth in our Growth Portfolio, which increased 12% and reflects the continued momentum across our diversified portfolio. The approval of Zenbexus, the first-in-class CELMoD, brings a new class of treatment to market for patients with multiple myeloma and is one of several recent pipeline milestones. As we look forward to additional late-stage data in the near term, we remain focused on executing with discipline, investing where we see the greatest opportunity and strengthening the foundation for sustainable growth.